These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 36453166)

  • 41. Novel uses of complement inhibitors in myasthenia gravis-Two case reports.
    Zadeh S; Price H; Drews R; Bouffard MA; Young LH; Narayanaswami P
    Muscle Nerve; 2024 Mar; 69(3):368-372. PubMed ID: 38205840
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nivolumab-associated myositis myocarditis and myasthenia and anti-striated muscle antibodies.
    Fazal M; Prentice DA; Kho LK; Fysh E
    Intern Med J; 2020 Aug; 50(8):1003-1006. PubMed ID: 33306231
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Managing suspected myasthenia gravis and myositis induced by pembrolizumab in a Jehovah's Witness sarcoma patient.
    Hutchinson A; Eskens D; Chan A; Bhargava A; Bycroft R
    J Oncol Pharm Pract; 2024 Jul; 30(5):950-953. PubMed ID: 38523425
    [TBL] [Abstract][Full Text] [Related]  

  • 44. How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors.
    Jordan B; Benesova K; Hassel JC; Wick W; Jordan K
    ESMO Open; 2021 Dec; 6(6):100317. PubMed ID: 34839103
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Case Report: The Neuromusclar Triad of Immune Checkpoint Inhibitors: A Case Report of Myositis, Myocarditis, and Myasthenia Gravis Overlap Following Toripalimab Treatment.
    Luo YB; Tang W; Zeng Q; Duan W; Li S; Yang X; Bi F
    Front Cardiovasc Med; 2021; 8():714460. PubMed ID: 34485412
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review.
    Jones SC; Sorbello A; Boucher RM
    Drug Saf; 2011 Oct; 34(10):839-47. PubMed ID: 21879778
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
    Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
    Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [An autopsy case of nivolumab-induced myasthenia gravis and myositis].
    Sawai T; Hosokawa T; Shigekiyo T; Ogawa S; Sano E; Arawaka S
    Rinsho Shinkeigaku; 2019 Jun; 59(6):360-364. PubMed ID: 31142711
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A systematic review of myasthenia gravis complicated with myocarditis.
    Cheng W; Sun T; Liu C; Zhou Z; Duan J; Zhao Y; Yang M; Chen P
    Brain Behav; 2021 Aug; 11(8):e2242. PubMed ID: 34105901
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical spectrum of neuromuscular complications after immune checkpoint inhibition.
    Puwanant A; Isfort M; Lacomis D; Živković SA
    Neuromuscul Disord; 2019 Feb; 29(2):127-133. PubMed ID: 30638612
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Risk Factors Associated with Immune Checkpoint Inhibitor-Related Pneumonitis.
    Asada M; Mikami T; Niimura T; Zamami Y; Uesawa Y; Chuma M; Ishizawa K
    Oncology; 2021; 99(4):256-259. PubMed ID: 33477139
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Analysis on the risk of myasthenia gravis related to immune checkpoint inhibitors based on the US FDA Adverse Event Reporting System.
    Kong Q; Wang H; Ren X; Zhuo Y; Peng J
    Cancer Med; 2023 Oct; 12(19):19491-19499. PubMed ID: 37724594
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Immune checkpoint inhibitor-induced anti-striational antibodies in myasthenia gravis and myositis: a case report].
    Sugiyama Y; Esa Y; Watanabe A; Kobayashi J; Suzuki S; Takahashi D
    Rinsho Shinkeigaku; 2021 Sep; 61(9):630-634. PubMed ID: 34433744
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Checkpoint inhibitor myasthenia-like syndrome and myositis associated with extraocular muscle atrophy.
    Ozarczuk TRA; Prentice DA; Kho LK; vanHeerden J
    J Clin Neurosci; 2020 Jan; 71():271-272. PubMed ID: 31889642
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognosis of immune checkpoint inhibitor-induced myasthenia gravis: a single center experience and systematic review.
    Qin Y; Chen S; Gui Q; Zhang T; Li Y; Du Z; Lv Y; Du X; Hu Y; Liu Z
    Front Neurol; 2024; 15():1372861. PubMed ID: 38633537
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database.
    Mikami T; Liaw B; Asada M; Niimura T; Zamami Y; Green-LaRoche D; Pai L; Levy M; Jeyapalan S
    J Neurooncol; 2021 Mar; 152(1):135-144. PubMed ID: 33423151
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Myasthenia triggered by immune checkpoint inhibitors: New case and literature review.
    Gonzalez NL; Puwanant A; Lu A; Marks SM; Živković SA
    Neuromuscul Disord; 2017 Mar; 27(3):266-268. PubMed ID: 28109638
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Myocarditis related to immune checkpoint inhibitors treatment: two case reports and literature review.
    Chen Y; Jia Y; Liu Q; Shen Y; Zhu H; Dong X; Huang J; Lu J; Yin Q
    Ann Palliat Med; 2021 Jul; 10(7):8512-8517. PubMed ID: 34263614
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature.
    Safa H; Johnson DH; Trinh VA; Rodgers TE; Lin H; Suarez-Almazor ME; Fa'ak F; Saberian C; Yee C; Davies MA; Tummala S; Woodman K; Abdel-Wahab N; Diab A
    J Immunother Cancer; 2019 Nov; 7(1):319. PubMed ID: 31753014
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neurological Manifestations Related to Immune Checkpoint Inhibitors: Reverse Translational Research by Using the European Real-World Safety Data.
    Ruggiero R; Stelitano B; Fraenza F; di Mauro G; Scavone C; Sportiello L; Rafaniello C; Di Napoli R; Danesi R; Del Re M; Rossi F; Capuano A
    Front Oncol; 2022; 12():824511. PubMed ID: 35372076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.